Ublituximab is in development for the treatment of relapsing forms of multiple sclerosis (MS). MS is an autoimmune condition in which inflammation damages the protective insulation around nerves as well as the nerves themselves. MS can affect the brain and spinal cord, causing a wide range of potential symptoms, including problems with vision, arm or leg movement, sensation, or balance. The exact cause of MS is unclear, but it is thought that a combination of genetic and environmental factors are involved. Relapsing-remitting MS (RRMS) is the most common form, where the patient has attacks (relapses) between periods with few or no symptoms (remissions). There is currently no cure for MS, and there remains an unmet need for more treatments that are effective at reducing relapse rates.
Ublituximab for treating multiple sclerosis
Ublituximab is in development for the treatment of relapsing forms of multiple sclerosis (MS). MS is an autoimmune condition in which inflammation damages the protective insulation around nerves as well as the nerves themselves.
Interventions:
Ublituximab (TG-1101; LFB-R603)
Indications:
Multiple sclerosis (MS)
Therapeutic Areas:
Neurology
Year:
2022